Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 5/2018

01-10-2018 | Review Article

Recent Developments in the Diagnosis and Management of Photosensitive Disorders

Authors: Amanda F. Nahhas, David M. Oberlin, Taylor L. Braunberger, Henry W. Lim

Published in: American Journal of Clinical Dermatology | Issue 5/2018

Login to get access

Abstract

Photodermatoses occur in males and females of all races and ages. Onset can be variable in timing and influenced by genetic and environmental factors. Photodermatoses are broadly classified as immunologically mediated, chemical- and drug-induced, photoaggravated, and genetic (defective DNA repair or chromosomal instability) diseases. Advances in the field have led to improved recognition and treatment of many photodermatoses. The purpose of this focused review is to provide an update on the diagnosis and management of a variety of photodermatoses, both common and less common, with review of recent updates in the literature pertaining to their diagnosis and management.
Literature
1.
Lim H, Hawk JLM, Rosen C. Photodermatoses. In: Bolognia J, Schaffer JV, Cerroni L, editors. Dermatology. 4th ed. London: Elsevier; 2018. p. 1548–68.
2.
Oakley A, James WD. Photosensitivity. StatPearls. Treasure Island: StatPearls Publishing LLC; 2017.
3.
Oakley A, Ramsey ML. Polymorphic light eruption StatPearls. Treasure Island: StatPearls Publishing LLC; 2017.
4.
Wolf P, Byrne SN, Gruber-Wackernagel A. New insights into the mechanisms of polymorphic light eruption: resistance to ultraviolet radiation-induced immune suppression as an aetiological factor. Exp Dermatol. 2009;18(4):350–6.PubMedCrossRef
5.
Pao C, Norris PG, Corbett M, Hawk JL. Polymorphic light eruption: prevalence in Australia and England. Br J Dermatol. 1994;130(1):62–4.PubMedCrossRef
6.
Gruber-Wackernagel A, Byrne SN, Wolf P. Polymorphous light eruption: clinic aspects and pathogenesis. Dermatol Clin. 2014;32(3):315–34 (viii).PubMedCrossRef
7.
Stratigos AJ, Antoniou C, Katsambas AD. Polymorphous light eruption. J Eur Acad Dermatol Venereol. 2002;16(3):193–206.PubMedCrossRef
8.
Rhodes LE, Bock M, Janssens AS, Ling TC, Anastasopoulou L, Antoniou C, et al. Polymorphic light eruption occurs in 18% of Europeans and does not show higher prevalence with increasing latitude: multicenter survey of 6895 individuals residing from the Mediterranean to Scandinavia. J Investig Dermatol. 2010;130(2):626–8.PubMedCrossRef
9.
10.
Epstein S. Studies in abnormal human sensitivity to light: IV. Photoallergic concept of prurigo aestivalis. J Investig Dermatol. 1942;5(6):289–98.CrossRef
11.
Watanabe M, Yamanouchi H, Ogawa F, Katayama I. Polymorphous light eruption. A case report and consideration of the hardening mechanism. Dermatology. 1999;199(2):158–61.PubMedCrossRef
12.
Gonzalez-Amaro R, Baranda L, Salazar-Gonzalez JF, Abud-Mendoza C, Moncada B. Immune sensitization against epidermal antigens in polymorphous light eruption. J Am Acad Dermatol. 1991;24(1):70–3.PubMedCrossRef
13.
Fukunaga A, Khaskhely NM, Ma Y, Sreevidya CS, Taguchi K, Nishigori C, et al. Langerhans cells serve as immunoregulatory cells by activating NKT cells. J Immunol (Baltimore, Md: 1950). 2010;185(8):4633–40.CrossRef
14.
Hadshiew IM, Treder-Conrad C, Bulow RV, Klette E, Mann T, Stab F, et al. Polymorphous light eruption (PLE) and a new potent antioxidant and UVA-protective formulation as prophylaxis. Photodermatol Photoimmunol Photomed. 2004;20(4):200–4.PubMedCrossRef
15.
Krutmann J, Grewe M. Involvement of cytokines, DNA damage, and reactive oxygen intermediates in ultraviolet radiation-induced modulation of intercellular adhesion molecule-1 expression. J Investig Dermatol. 1995;105(1 Suppl):67s–70s.PubMedCrossRef
16.
Grether-Beck S, Olaizola-Horn S, Schmitt H, Grewe M, Jahnke A, Johnson JP, et al. Activation of transcription factor AP-2 mediates UVA radiation- and singlet oxygen-induced expression of the human intercellular adhesion molecule 1 gene. Proc Natl Acad Sci USA. 1996;93(25):14586–91.PubMedCrossRef
17.
Millard TP, Fryer AA, McGregor JM. A protective effect of glutathione-S-transferase GSTP1*Val(105) against polymorphic light eruption. J Investig Dermatol. 2008;128(8):1901–5.PubMedCrossRef
18.
Zirbs M, Purner C, Buters JT, Effner R, Weidinger S, Ring J, et al. GSTM1, GSTT1 and GSTP1 gene polymorphism in polymorphous light eruption. J Eur Acad Dermatol Venereol. 2013;27(2):157–62.PubMedCrossRef
19.
McGregor JM, Grabczynska S, Vaughan R, Hawk JL, Lewis CM. Genetic modeling of abnormal photosensitivity in families with polymorphic light eruption and actinic prurigo. J Investig Dermatol. 2000;115(3):471–6.PubMedCrossRef
20.
Millard TP, Bataille V, Snieder H, Spector TD, McGregor JM. The heritability of polymorphic light eruption. J Investig Dermatol. 2000;115(3):467–70.PubMedCrossRef
21.
Elpern DJ, Morison WL, Hood AF. Papulovesicular light eruption. A defined subset of polymorphous light eruption. Arch Dermatol. 1985;121(10):1286–8.PubMedCrossRef
22.
Isedeh P, Lim HW. Polymorphous light eruption presenting as pinhead papular eruption on the face. J Drugs Dermatol. 2013;12(11):1285–6.PubMed
23.
Aljasser MI, Lui H, Ball NJ, Kalia S. Persistent polymorphous light eruption after ultraviolet al phototherapy. Photodermatol Photoimmunol Photomed. 2013;29(1):52–4.PubMedCrossRef
24.
Stratigos AJ, Antoniou C, Papadakis P, Papapostolou A, Sabatziotis D, Tranaka K, et al. Juvenile spring eruption: clinicopathologic features and phototesting results in 4 cases. J Am Acad Dermatol. 2004;50(2 Suppl):S57–60.PubMedCrossRef
25.
Lava SA, Simonetti GD, Ragazzi M, Guarino Gubler S, Bianchetti MG. Juvenile spring eruption: an outbreak report and systematic review of the literature. Br J Dermatol. 2013;168(5):1066–72.PubMedCrossRef
26.
Wolf P, Soyer HP, Fink-Puches R, Huff JC, Kerl H. Recurrent post-herpetic erythema multiforme mimicking polymorphic light and juvenile spring eruption: report of two cases in young boys. Br J Dermatol. 1994;131(3):364–7.PubMedCrossRef
27.
Norris PG, Hawk JL. Polymorphic light eruption. Photodermatol Photoimmunol Photomed. 1990;7(5):186–91.PubMed
28.
29.
30.
Janssens AS, Pavel S, Out-Luiting JJ, Willemze R, de Gruijl FR. Normalized ultraviolet (UV) induction of Langerhans cell depletion and neutrophil infiltrates after artificial UVB hardening of patients with polymorphic light eruption. Br J Dermatol. 2005;152(6):1268–74.PubMedCrossRef
31.
Wolf P, Gruber-Wackernagel A, Bambach I, Schmidbauer U, Mayer G, Absenger M, et al. Photohardening of polymorphic light eruption patients decreases baseline epidermal Langerhans cell density while increasing mast cell numbers in the papillary dermis. Exp Dermatol. 2014;23(6):428–30.PubMedCrossRef
32.
Yashar SS, Lim HW. Classification and evaluation of photodermatoses. Dermatol Ther. 2003;16(1):1–7.PubMedCrossRef
33.
Bylaite M, Grigaitiene J, Lapinskaite GS. Photodermatoses: classification, evaluation and management. Br J Dermatol. 2009;161(Suppl 3):61–8.PubMedCrossRef
34.
Man I, Dawe RS, Ferguson J. Artificial hardening for polymorphic light eruption: practical points from 10 years’ experience. Photodermatol Photoimmunol Photomed. 1999;15(3–4):96–9.PubMedCrossRef
35.
Corbett MF, Hawk JL, Herxheimer A, Magnus IA. Controlled therapeutic trials in polymorphic light eruption. Br J Dermatol. 1982;107(5):571–81.PubMedCrossRef
36.
Murphy GM, Hawk JL, Magnus IA. Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring. Br J Dermatol. 1987;116(3):379–86.PubMedCrossRef
37.
Norris PG, Hawk JL. Successful treatment of severe polymorphous light eruption with azathioprine. Arch Dermatol. 1989;125(10):1377–9.PubMedCrossRef
38.
Shipley DR, Hewitt JB. Polymorphic light eruption treated with cyclosporin. Br J Dermatol. 2001;144(2):446–7.PubMedCrossRef
39.
Tanew A, Radakovic S, Gonzalez S, Venturini M, Calzavara-Pinton P. Oral administration of a hydrophilic extract of Polypodium leucotomos for the prevention of polymorphic light eruption. J Am Acad Dermatol. 2012;66(1):58–62.PubMedCrossRef
40.
Caccialanza M, Percivalle S, Piccinno R, Brambilla R. Photoprotective activity of oral Polypodium leucotomos extract in 25 patients with idiopathic photodermatoses. Photodermatol Photoimmunol Photomed. 2007;23(1):46–7.PubMedCrossRef
41.
42.
Lane PR, Hogan DJ, Martel MJ, Reeder B, Irvine J. Actinic prurigo: clinical features and prognosis. J Am Acad Dermatol. 1992;26(5 Pt 1):683–92.PubMedCrossRef
43.
Hojyo-Tomoka T, Vega-Memije E, Granados J, Flores O, Cortes-Franco R, Teixeira F, et al. Actinic prurigo: an update. Int J Dermatol. 1995;34(6):380–4.PubMedCrossRef
44.
Vega Memije ME, Cuevas Gonzalez JC, Hojyo-Tomoka MT, Rodriguez Lobato E. Actinic prurigo as a hypersensitivity reaction type 4. Int J Dermatol. 2017;56(6):e135–6.PubMedCrossRef
45.
Hönigsmann H, Hojyo-Tomoka MT. Polymorphous light eruption, hydroa vacciniforme, and actinic prurigo. In: Lim H, Hönigsmann H, Hawk J, editors. Photodermatology. New York: Informa Healthcare; 2007. p. 149–68.
46.
Menage Hd, Vaughan RW, Baker CS, Page G, Proby CM, Breathnach SM, et al. HLA-DR4 may determine expression of actinic prurigo in British patients. J Investig Dermatol. 1996;106(2):362–7.CrossRef
47.
Dawe RS, Collins P, Ferguson J, O’Sullivan A. Actinic prurigo and HLA-DR4. J Investig Dermatol. 1997;108(2):233–4.PubMedCrossRef
48.
Hojyo-Tomoka T, Granados J, Vargas-Alarcon G, Yamamoto-Furusho JK, Vega-Memije E, Cortes-Franco R, et al. Further evidence of the role of HLA-DR4 in the genetic susceptibility to actinic prurigo. J Am Acad Dermatol. 1997;36(6 Pt 1):935–7.PubMedCrossRef
49.
50.
Sheridan DP, Lane PR, Irvine J, Martel MJ, Hogan DJ. HLA typing in actinic prurigo. J Am Acad Dermatol. 1990;22(6 Pt 1):1019–23.PubMedCrossRef
51.
Bernal JE, Duran de Rueda MM, Ordonez CP, Duran C, de Brigard D. Actinic prurigo among the Chimila Indians in Colombia: HLA studies. J Am Acad Dermatol. 1990;22(6 Pt 1):1049–51.PubMedCrossRef
52.
Bernal JE, Duran de Rueda MM, de Brigard D. Human lymphocyte antigen in actinic prurigo. J Am Acad Dermatol. 1988;18(2 Pt 1):310–2.PubMed
53.
Grabczynska SA, Carey BS, McGregor JM, Hawk JL, Vaughan RW. Tumour necrosis factor alpha promoter polymorphism at position − 308 is not associated with actinic prurigo. Clin Exp Dermatol. 2001;26(8):700–4.PubMedCrossRef
54.
Ross G, Foley P, Baker C. Actinic prurigo. Photodermatol Photoimmunol Photomed. 2008;24(5):272–5.PubMedCrossRef
55.
Choi D, Kannan S, Lim HW. Evaluation of patients with photodermatoses. Dermatol Clin. 2014;32(3):267–75 (vii).PubMedCrossRef
56.
Hojyo-Tomoka MT, Vega-Memije ME, Cortes-Franco R, Dominguez-Soto L. Diagnosis and treatment of actinic prurigo. Dermatol Ther. 2003;16(1):40–4.PubMedCrossRef
57.
Cuevas-Gonzalez JC, Lievanos-Estrada Z, Vega-Memije ME, Hojyo-Tomoka MT, Dominguez-Soto L. Correlation of serum IgE levels and clinical manifestations in patients with actinic prurigo. An Bras Dermatol. 2016;91(1):23–6.PubMedPubMedCentralCrossRef
58.
Crouch R, Foley P, Baker C. Actinic prurigo: a retrospective analysis of 21 cases referred to an Australian photobiology clinic. Australas J Dermatol. 2002;43(2):128–32.PubMedCrossRef
59.
Kerr AC, Ferguson J. Actinic prurigo deterioration due to degradation of DermaGard window film. Br J Dermatol. 2007;157(3):619–20.PubMedCrossRef
60.
Lane PR, Moreland AA, Hogan DJ. Treatment of actinic prurigo with intermittent short-course topical 0.05% clobetasol 17-propionate. A preliminary report. Arch Dermatol. 1990;126(9):1211–3.PubMedCrossRef
61.
van de Pas CB, Kelly DA, Seed PT, Young AR, Hawk JL, Walker SL. Ultraviolet-radiation-induced erythema and suppression of contact hypersensitivity responses in patients with polymorphic light eruption. J Investig Dermatol. 2004;122(2):295–9.PubMedCrossRef
62.
63.
Arrese JE, Dominguez-Soto L, Hojyo-Tomoka MT, Vega-Memije E, Cortes-Franco R, Guevara E, et al. Effectors of inflammation in actinic prurigo. J Am Acad Dermatol. 2001;44(6):957–61.PubMedCrossRef
64.
Torres-Alvarez B, Castanedo-Cazares JP, Moncada B. Pentoxifylline in the treatment of actinic prurigo. A preliminary report of 10 patients. Dermatology. 2004;208(3):198–201.PubMedCrossRef
65.
Lestarini D, Khoo LS, Goh CL. The clinical features and management of actinic prurigo: a retrospective study. Photodermatol Photoimmunol Photomed. 1999;15(5):183–7.PubMedCrossRef
66.
Umana A, Gomez A, Duran MM, Porras L. Lymphocyte subtypes and adhesion molecules in actinic prurigo: observations with cyclosporin A. Int J Dermatol. 2002;41(3):139–45.PubMedCrossRef
67.
Gupta G, Man I, Kemmett D. Hydroa vacciniforme: a clinical and follow-up study of 17 cases. J Am Acad Dermatol. 2000;42(2 Pt 1):208–13.PubMedCrossRef
68.
Nitiyarom R, Wongpraparut C. Hydroa vacciniforme and solar urticaria. Dermatol Clin. 2014;32(3):345–53 (viii).PubMedCrossRef
69.
Chen CC, Chang KC, Medeiros LJ, Lee JY. Hydroa vacciniforme and hydroa vacciniforme-like T-cell lymphoma: an uncommon event for transformation. J Cutan Pathol. 2016;43(12):1102–11.PubMedCrossRef
70.
Iwatsuki K, Satoh M, Yamamoto T, Oono T, Morizane S, Ohtsuka M, et al. Pathogenic link between hydroa vacciniforme and Epstein–Barr virus-associated hematologic disorders. Arch Dermatol. 2006;142(5):587–95.PubMedCrossRef
71.
Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein–Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8–9 September 2008. Ann Oncol Off J Eur Soc Med Oncol. 2009;20(9):1472–82.CrossRef
72.
Cho KH, Lee SH, Kim CW, Jeon YK, Kwon IH, Cho YJ, et al. Epstein-Barr virus-associated lymphoproliferative lesions presenting as a hydroa vacciniforme-like eruption: an analysis of six cases. Br J Dermatol. 2004;151(2):372–80.PubMedCrossRef
73.
Lee HY, Baek JO, Lee JR, Park SH, Jeon IS, Roh JY. Atypical hydroa vacciniforme-like Epstein–Barr virus associated T/NK-cell lymphoproliferative disorder. Am J Dermatopathol. 2012;34(8):e119–24.PubMedCrossRef
74.
Barrionuevo C, Anderson VM, Zevallos-Giampietri E, Zaharia M, Misad O, Bravo F, et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol AIMM. 2002;10(1):7–14.PubMed
75.
Sonnex TS, Hawk JL. Hydroa vacciniforme: a review of ten cases. Br J Dermatol. 1988;118(1):101–8.PubMedCrossRef
76.
Chantorn R, Lim HW, Shwayder TA. Photosensitivity disorders in children: part I. J Am Acad Dermatol. 2012;67(6):1093.e1–18 (quiz 111-2).CrossRef
77.
Huggins RH, Leithauser LA, Eide MJ, Hexsel CL, Jacobsen G, Lim HW. Quality of life assessment and disease experience of patient members of a web-based hydroa vacciniforme support group. Photodermatol Photoimmunol Photomed. 2009;25(4):209–15.PubMedCrossRef
78.
Millard TP, Hawk JL. Photosensitivity disorders: cause, effect and management. Am J Clin Dermatol. 2002;3(4):239–46.PubMedCrossRef
79.
Bruderer P, Shahabpour M, Christoffersen S, Andre J, Ledoux M. Hydroa vacciniforme treated by a combination of beta-carotene and canthaxanthin. Dermatology. 1995;190(4):343–5.PubMedCrossRef
80.
Goldgeier MH, Nordlund JJ, Lucky AW, Sibrack LA, McCarthy MJ, McGuire J. Hydroa vacciniforme: diagnosis and therapy. Arch Dermatol. 1982;118(8):588–91.PubMedCrossRef
81.
Blackwell V, McGregor JM, Hawk JL. Hydroa vacciniforme presenting in an adult successfully treated with cyclosporin A. Clin Exp Dermatol. 1998;23(2):73–6.PubMedCrossRef
82.
Modeste AB, Cordel N, Balguerie X, Leroy D, Lauret P, Joly P. Hydroa vacciniforme: dietary fish oil. Ann Dermatol Venereol. 2001;128(3 Pt 1):247–9.PubMed
83.
Lysell J, Wiegleb Edstrom D, Linde A, Carlsson G, Malmros-Svennilson J, Westermark A, et al. Antiviral therapy in children with hydroa vacciniforme. Acta Derm Venereol. 2009;89(4):393–7.PubMedCrossRef
84.
Menage H, Ross JS, Norris PG, Hawk JL, White IR. Contact and photocontact sensitization in chronic actinic dermatitis: sesquiterpene lactone mix is an important allergen. Br J Dermatol. 1995;132(4):543–7.PubMedCrossRef
85.
Lim HW, Morison WL, Kamide R, Buchness MR, Harris R, Soter NA. Chronic actinic dermatitis. An analysis of 51 patients evaluated in the United States and Japan. Arch Dermatol. 1994;130(10):1284–9.PubMedCrossRef
86.
Russell SC, Dawe RS, Collins P, Man I, Ferguson J. The photosensitivity dermatitis and actinic reticuloid syndrome (chronic actinic dermatitis) occurring in seven young atopic dermatitis patients. Br J Dermatol. 1998;138(3):496–501.PubMedCrossRef
87.
Ogboli MI, Rhodes LE. Chronic actinic dermatitis in young atopic dermatitis sufferers. Br J Dermatol. 2000;142(4):845.PubMedCrossRef
88.
Que SK, Brauer JA, Soter NA, Cohen DE. Chronic actinic dermatitis: an analysis at a single institution over 25 years. Dermatitis Contact Atopic Occup Drug. 2011;22(3):147–54.
89.
Tan KW, Haylett AK, Ling TC, Rhodes LE. Comparison of demographic and photobiological features of chronic actinic dermatitis in patients with lighter vs darker skin types. JAMA Dermatol. 2017;153(5):427–35.PubMedPubMedCentralCrossRef
90.
Lim HW, Cohen D, Soter NA. Chronic actinic dermatitis: results of patch and photopatch tests with Compositae, fragrances, and pesticides. J Am Acad Dermatol. 1998;38(1):108–11.PubMedCrossRef
91.
Hawk J, Lim HW. Chronic actinic dermatitis. In: Lim H, Hönigsmann H, Hawk J, editors. Photodermatology. New York: Informa Healthcare; 2007.
92.
Hawk J. Photodermatology. New York: Oxford University Press; 1999.
93.
94.
95.
Hawk JL, Magnus IA. Chronic actinic dermatitis–an idiopathic photosensitivity syndrome including actinic reticuloid and photosensitive eczema [proceedings]. Br J Dermatol. 1979;101(Suppl 17):24.PubMed
96.
Agar N, Morris S, Russell-Jones R, Hawk J, Whittaker S. Case report of four patients with erythrodermic cutaneous T-cell lymphoma and severe photosensitivity mimicking chronic actinic dermatitis. Br J Dermatol. 2009;160(3):698–703.PubMedCrossRef
97.
Moseley H, Ferguson J. The risk to normal and photosensitive individuals from exposure to light from compact fluorescent lamps. Photodermatol Photoimmunol Photomed. 2011;27(3):131–7.PubMedCrossRef
98.
Bhari N, Gupta S. Tacrolimus 0.1% ointment applied under occlusion using cling film clears chronic actinic dermatitis resistant to systemic treatment. Int J Dermatol. 2017;56(6):e139–41.PubMedCrossRef
99.
Norris PG, Camp RD, Hawk JL. Actinic reticuloid: response to cyclosporine. J Am Acad Dermatol. 1989;21(2 Pt 1):307–9.PubMedCrossRef
100.
Gardeazabal J, Arregui MA, Gil N, Landa N, Raton JA, Diaz-Perez JL. Successful treatment of musk ketone-induced chronic actinic dermatitis with cyclosporine and PUVA. J Am Acad Dermatol. 1992;27(5 Pt 2):838–42.PubMedCrossRef
101.
Murphy GM, Maurice PD, Norris PG, Morris RW, Hawk JL. Azathioprine treatment in chronic actinic dermatitis: a double-blind controlled trial with monitoring of exposure to ultraviolet radiation. Br J Dermatol. 1989;121(5):639–46.PubMedCrossRef
102.
Leigh IM, Hawk JL. Treatment of chronic actinic dermatitis with azathioprine. Br J Dermatol. 1984;110(6):691–5.PubMedCrossRef
103.
Thomson MA, Stewart DG, Lewis HM. Chronic actinic dermatitis treated with mycophenolate mofetil. Br J Dermatol. 2005;152(4):784–6.PubMedCrossRef
104.
Vesely MD, Imaeda S, King BA. Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis. JAAD Case Rep. 2017;3(1):4–6.PubMedCrossRef
105.
106.
Dawe RS, Crombie IK, Ferguson J. The natural history of chronic actinic dermatitis. Arch Dermatol. 2000;136(10):1215–20.PubMedCrossRef
107.
Sugita K, Shimauchi T, Tokura Y. Chronic actinic dermatitis associated with adult T-cell leukemia. J Am Acad Dermatol. 2005;52(2 Suppl 1):38–40.PubMedCrossRef
108.
Adachi Y, Horio T. Chronic actinic dermatitis in a patient with adult T-cell leukemia. Photodermatol Photoimmunol Photomed. 2008;24(3):147–9.PubMedCrossRef
109.
Thomsen K. The development of Hodgkin’s disease in a patient with actinic reticuloid. Clin Exp Dermatol. 1977;2(2):109–13.PubMedCrossRef
110.
De Silva BD, McLaren K, Kavanagh GM. Photosensitive mycosis fungoides or actinic reticuloid? Br J Dermatol. 2000;142(6):1221–7.PubMedCrossRef
111.
Bilsland D, Crombie IK, Ferguson J. The photosensitivity dermatitis and actinic reticuloid syndrome: no association with lymphoreticular malignancy. Br J Dermatol. 1994;131(2):209–14.PubMedCrossRef
112.
Norris PG, Newton JA, Camplejohn RS, Hawk JL. A flow cytometric study of actinic reticuloid. Clin Exp Dermatol. 1989;14(2):128–31.PubMedCrossRef
113.
Kerr HA, Lim HW. Photodermatoses in African Americans: a retrospective analysis of 135 patients over a 7-year period. J Am Acad Dermatol. 2007;57(4):638–43.PubMedCrossRef
114.
Nakamura M, Henderson M, Jacobsen G, Lim HW. Comparison of photodermatoses in African-Americans and Caucasians: a follow-up study. Photodermatol Photoimmunol Photomed. 2014;30(5):231–6.PubMedCrossRef
115.
Beattie P, Dawe RS, Ibbotson SH, Ferguson J. Characteristics and prognosis or idiopathic solar urticaria: a cohort of 87 cases. Arch Dermatol. 2003;139:1149–54.PubMedCrossRef
116.
Tuchinda C, Leenutaphong V, Sudtim S, Lim HW. Fixed solar urticaria induced by UVA and visible light: a report of a case. Photodermatol Photoimmunol Photomed. 2005;21:97–9.PubMedCrossRef
117.
Wessendorf U, Hanneken S, Haust M, Neumann NJ. Fixed solar urticaria with delayed onset. J Am Acad Dermatol. 2009;60(4):695–7.PubMedCrossRef
118.
Kaidbey KH, Kligman AM. Clinical and histological study of coal tar phototoxicity in humans. Arch Dermatol. 1977;113(5):592–5.PubMedCrossRef
119.
Kurumaji Y, Shono M. Drug-induced solar urticaria due to repirinast. Dermatology. 1994;188(2):117–21.PubMedCrossRef
120.
Tajima S, Fukunaga A, Nishigori C. A case of atorvastatin-induced solar urticaria. Photodermatol Photoimmunol Photomed. 2016;32(5–6):317–9.PubMedCrossRef
121.
Kuo S, Sivamani RK. UVB-sensitive solar urticaria possibly associated with terbinafine. Dermatol Online J. 2014;20(3).
122.
Yap LM, Foley PA, Crouch RB, Baker CS. Drug-induced solar urticaria due to tetracycline. Australas J Dermatol. 2000;41(3):181–4.PubMedCrossRef
123.
Morison WL. Solar urticaria due to progesterone compounds in oral contraceptives. Photodermatol Photoimmunol Photomed. 2003;19(3):155–6.PubMedCrossRef
124.
Hay RA, Pan JY. Persistent photosensitivity and solar urticaria following SJS/TEN. J Eur Acad Dermatol Venereol. 2015;29(1):190–1.PubMedCrossRef
125.
126.
127.
Tokura Y, Takigawa M, Yamauchi T, Yamada M. Solar urticaria: a case with good therapeutic response to cimetidine. Dermatologica. 1986;173(5):224–8.PubMedCrossRef
128.
Neittaanmaki H, Jaaskelainen T, Harvima RJ, Fraki JE. Solar urticaria: demonstration of histamine release and effective treatment with doxepin. Photodermatology. 1989;6(1):52–5.PubMed
129.
Grundmann SA, Stander S, Luger TA, Beissert S. Antihistamine combination treatment for solar urticaria. Br J Dermatol. 2008;158(6):1384–6.PubMedCrossRef
130.
Levi A, Enk CD. Treatment of solar urticaria using antihistamine and leukotriene receptor antagonist combinations tailored to disease severity. Photodermatol Photoimmunol Photomed. 2015;31(6):302–6.PubMedCrossRef
131.
Beissert S, Stander H, Schwarz T. UVA rush hardening for the treatment of solar urticaria. J Am Acad Dermatol. 2000;42(6):1030–2.PubMedCrossRef
132.
Dawe RS, Ferguson J. Prolonged benefit following ultraviolet A phototherapy for solar urticaria. Br J Dermatol. 1997;137(1):144–8.PubMedCrossRef
133.
Calzavara-Pinton P, Zane C, Rossi M, Sala R, Venturini M. Narrowband ultraviolet B phototherapy is a suitable treatment option for solar urticaria. J Am Acad Dermatol. 2012;67(1):e5–9.PubMedCrossRef
134.
Duschet P, Leyen P, Schwarz T, Hocker P, Greiter J, Gschnait F. Solar urticaria—effective treatment by plasmapheresis. Clin Exp Dermatol. 1987;12(3):185–8.PubMedCrossRef
135.
136.
Aubin F, Avenel-Audran M, Jeanmougin M, Adamski H, Peyron JL, Marguery MC, et al. Omalizumab in patients with severe and refractory solar urticaria: a phase II multicentric study. J Am Acad Dermatol. 2016;74(3):574–5.PubMedCrossRef
137.
Baliu-Pique C, Aguilera Peiro P. Three cases of solar urticaria successfully treated with omalizumab. J Eur Acad Dermatol Venereol. 2016;30(4):704–6.PubMedCrossRef
138.
Maksimovic L, Fremont G, Jeanmougin M, Dubertret L, Viguier M. Solar urticaria successfully treated with intravenous immunoglobulins. Dermatology. 2009;218(3):252–4.PubMedCrossRef
139.
Frank J, Poblete-Butierrez PA, Lang E. Porphyria. In: Bolognia J, Jorizo JL, Schaffer JV, editors. Dermatology. 4th ed. London: Elsevier; 2018. p. 773–83.
140.
Balwani M, Naik H, Anderson KE, Bissell DM, Bloomer J, Bonkovsky HL, et al. Clinical, biochemical, and genetic characterization of North American patients with erythropoietic protoporphyria and X-linked protoporphyria. JAMA Dermatol. 2017;153(8):789–96.PubMedPubMedCentralCrossRef
141.
Horner ME, Alikhan A, Tintle S, Tortorelli S, Davis DM, Hand JL. Cutaneous porphyrias part I: epidemiology, pathogenesis, presentation, diagnosis, and histopathology. Int J Dermatol. 2013;52(12):1464–80.PubMedCrossRef
142.
Parker M, Corrigall AV, Hift RJ, Meissner PN. Molecular characterization of erythropoietic protoporphyria in South Africa. Br J Dermatol. 2008;159(1):182–91.PubMedCrossRef
143.
Marko PB, Miljkovic J, Gorenjak M, Povalej P, Kansky A. Erythropoietic protoporphyria patients in Slovenia. Acta dermatovenerologica Alpina, Pannonica, et Adriatica. 2007;16(3):99–102.PubMed
144.
Poh-Fitzpatrick MB. The “priming phenomenon” in the acute phototoxicity of erythropoietic protoporphyria. J Am Acad Dermatol. 1989;21(2 Pt 1):311.PubMedCrossRef
145.
146.
Holme SA, Whatley SD, Roberts AG, Anstey AV, Elder GH, Ead RD, et al. Seasonal palmar keratoderma in erythropoietic protoporphyria indicates autosomal recessive inheritance. J Investig Dermatol. 2009;129(3):599–605.PubMedCrossRef
147.
148.
Balwani M, Bloomer J, Desnick R, Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. Erythropoietic protoporphyria, autosomal recessive. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington; 1993–2018.
149.
Whatley SD, Badminton MN. Role of genetic testing in the management of patients with inherited porphyria and their families. Ann Clin Biochem. 2013;50(Pt 3):204–16.PubMedCrossRef
150.
Wahlin S, Srikanthan N, Hamre B, Harper P, Brun A. Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2008;14(9):1340–6.
151.
Spelt JM, de Rooij FW, Wilson JH, Zandbergen AA. Vitamin D deficiency in patients with erythropoietic protoporphyria. J Inherit Metab Dis. 2010;33(Suppl 3):S1–4.PubMedCrossRef
152.
McCullough AJ, Barron D, Mullen KD, Petrelli M, Park MC, Mukhtar H, et al. Fecal protoporphyrin excretion in erythropoietic protoporphyria: effect of cholestyramine and bile acid feeding. Gastroenterology. 1988;94(1):177–81.PubMedCrossRef
153.
Bosio GN, Breitenbach T, Parisi J, Reigosa M, Blaikie FH, Pedersen BW, et al. Antioxidant beta-carotene does not quench singlet oxygen in mammalian cells. J Am Chem Soc. 2013;135(1):272–9.PubMedCrossRef
154.
Tu JH, Sheu SL, Teng JM. Novel treatment using cimetidine for erythropoietic protoporphyria in children. JAMA Dermatol. 2016;152(11):1258–61.PubMedCrossRef
155.
Yamamoto S, Hirano Y, Horie Y. Cimetidine reduces erythrocyte protoporphyrin in erythropoietic protoporphyria. Am J Gastroenterol. 1993;88(9):1465–6.PubMed
156.
Eefsen M, Rasmussen A, Wulf HC, Brock A, Hansen BA. Erythropoietic protoporphyria and pretransplantation treatment with nonbiological liver assist devices. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2007;13(5):655–7.
157.
Garcia-Martin P, De Argila D, To-Figueras J, Llamas-Velasco M, Fraga J, Garcia-Diez A. Phototolerance induced by narrow-band UVB phototherapy in severe erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed. 2012;28(5):261–3.PubMedCrossRef
158.
Jansen R, Wang SQ, Burnett M, Osterwalder U, Lim HW. Photoprotection: part I. Photoprotection by naturally occurring, physical, and systemic agents. J Am Acad Dermatol. 2013;69(6):853.e1–12 (quiz 65–66).CrossRef
159.
Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48–59.PubMedPubMedCentralCrossRef
160.
Bustamante J, Bredeston L, Malanga G, Mordoh J. Role of melanin as a scavenger of active oxygen species. Pigment Cell Res. 1993;6(5):348–53.PubMedCrossRef
161.
Kollias N, Sayre RM, Zeise L, Chedekel MR. Photoprotection by melanin. J Photochem Photobiol B. 1991;9(2):135–60.PubMedCrossRef
162.
Minder EI, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders. Clin Pharmacokinet. 2017;56(8):815–23.PubMedCrossRef
163.
Anstey AV, Hift RJ. Liver disease in erythropoietic protoporphyria: insights and implications for management. Gut. 2007;56(7):1009–18.PubMedPubMedCentral
164.
Singal AK, Parker C, Bowden C, Thapar M, Liu L, McGuire BM. Liver transplantation in the management of porphyria. Hepatology (Baltimore, Md). 2014;60(3):1082–9.PubMedCentralCrossRef
165.
Nowaczyk MJM. Smith–Lemli–Opitz syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington; 1993–2018.
166.
Nowaczyk MJ, Tan M, Hamid JS, Allanson JE. Smith–Lemli–Opitz syndrome: objective assessment of facial phenotype. Am J Med Genet Part A. 2012;158a(5):1020–8.PubMedCrossRef
167.
Tint GS, Irons M, Elias ER, Batta AK, Frieden R, Chen TS, et al. Defective cholesterol biosynthesis associated with the Smith–Lemli–Opitz syndrome. N Engl J Med. 1994;330(2):107–13.PubMedCrossRef
168.
Cunniff C, Kratz LE, Moser A, Natowicz MR, Kelley RI. Clinical and biochemical spectrum of patients with RSH/Smith–Lemli–Opitz syndrome and abnormal cholesterol metabolism. Am J Med Genet. 1997;68(3):263–9.PubMedCrossRef
169.
Johnson VP. Smith–Lemli–Opitz syndrome: review and report of two affected siblings. Zeitschrift fur Kinderheilkunde. 1975;119(4):221–34.PubMedCrossRef
170.
171.
Chasalow FI, Blethen SL, Taysi K. Possible abnormalities of steroid secretion in children with Smith–Lemli–Opitz syndrome and their parents. Steroids. 1985;46(4–5):827–43.PubMedCrossRef
172.
Pinsky L, Digeorge AM. A familial syndrome of facial and skeletal anomalies associated with genital abnormality in the male and noraml genitals in the female: another cause of male pseudohermaphroditism. J Pediatr. 1965;66:1049–54.PubMedCrossRef
173.
Chemaitilly W, Goldenberg A, Baujat G, Thibaud E, Cormier-Daire V, Abadie V. Adrenal insufficiency and abnormal genitalia in a 46XX female with Smith–Lemli–Opitz syndrome. Horm Res. 2003;59(5):254–6.PubMed
174.
Lee RW, Conley SK, Gropman A, Porter FD, Baker EH. Brain magnetic resonance imaging findings in Smith–Lemli–Opitz syndrome. Am J Med Genet Part A. 2013;161a(10):2407–19.PubMed
175.
Lin AE, Ardinger HH, Ardinger RH Jr, Cunniff C, Kelley RI. Cardiovascular malformations in Smith–Lemli–Opitz syndrome. Am J Med Genet. 1997;68(3):270–8.PubMedCrossRef
176.
Finley SC, Finley WH, Monsky DB. Cataracts in a girl with features of the Smith–Lemli–Opitz syndrome. J Pediatr. 1969;75(4):706–7.PubMedCrossRef
177.
Atchaneeyasakul LO, Linck LM, Connor WE, Weleber RG, Steiner RD. Eye findings in 8 children and a spontaneously aborted fetus with RSH/Smith–Lemli–Opitz syndrome. Am J Med Genet. 1998;80(5):501–5.PubMedCrossRef
178.
Ryan AK, Bartlett K, Clayton P, Eaton S, Mills L, Donnai D, et al. Smith–Lemli–Opitz syndrome: a variable clinical and biochemical phenotype. J Med Genet. 1998;35(7):558–65.PubMedPubMedCentralCrossRef
179.
Krajewska-Walasek M, Gradowska W, Ryzko J, Socha P, Chmielik J, Szaplyko W, et al. Further delineation of the classical Smith–Lemli–Opitz syndrome phenotype at different patient ages: clinical and biochemical studies. Clin Dysmorphol. 1999;8(1):29–40.PubMedCrossRef
180.
Anstey AV, Taylor CR. Photosensitivity in the Smith–Lemli–Opitz syndrome: the US experience of a new congenital photosensitivity syndrome. J Am Acad Dermatol. 1999;41(1):121–3.PubMedCrossRef
181.
Starck L, Lovgren-Sandblom A, Bjorkhem I. Cholesterol treatment forever? The first Scandinavian trial of cholesterol supplementation in the cholesterol-synthesis defect Smith–Lemli–Opitz syndrome. J Intern Med. 2002;252(4):314–21.PubMedCrossRef
182.
Azurdia RM, Anstey AV, Rhodes LE. Cholesterol supplementation objectively reduces photosensitivity in the Smith–Lemli–Opitz syndrome. Br J Dermatol. 2001;144(1):143–5.PubMedCrossRef
183.
Calmels N, Greff G, Obringer C, Kempf N, Gasnier C, Tarabeux J, et al. Uncommon nucleotide excision repair phenotypes revealed by targeted high-throughput sequencing. Orphanet J Rare Dis. 2016;22(11):26.CrossRef
184.
Cleaver JE, Lam ET, Revet I. Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity. Nat Rev Genet. 2009;10(11):756–68.PubMedCrossRef
185.
Kleijer WJ, Laugel V, Berneburg M, Nardo T, Fawcett H, Gratchev A, et al. Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum. Cockayne syndrome and trichothiodystrophy. DNA Repair. 2008;7(5):744–50.PubMedCrossRef
186.
Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol. 1994;130(8):1018–21.PubMedCrossRef
187.
Bradford PT, Goldstein AM, Tamura D, Khan SG, Ueda T, Boyle J, et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet. 2011;48(3):168–76.PubMedCrossRef
188.
Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol. 1987;123(2):241–50.PubMedCrossRef
189.
190.
DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. J Investig Dermatol. 2012;132(3 Pt 2):785–96.PubMedCrossRef
191.
Brooks PJ. The case for 8,5′-cyclopurine-2′-deoxynucleosides as endogenous DNA lesions that cause neurodegeneration in xeroderma pigmentosum. Neuroscience. 2007;145(4):1407–17.PubMedCrossRef
192.
Sethi M, Lehmann AR, Fawcett H, Stefanini M, Jaspers N, Mullard K, et al. Patients with xeroderma pigmentosum complementation groups C, E and V do not have abnormal sunburn reactions. Br J Dermatol. 2013;169(6):1279–87.PubMedCrossRef
193.
Kraemer KH, DiGiovanna JJ. Xeroderma pigmentosum. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews®. Seattle (WA): University of Washington; 1993–2018.
194.
Lai JP, Liu YC, Alimchandani M, Liu Q, Aung PP, Matsuda K, et al. The influence of DNA repair on neurological degeneration, cachexia, skin cancer and internal neoplasms: autopsy report of four xeroderma pigmentosum patients (XP-A, XP-C and XP-D). Acta Neuropathol Commun. 2013;8(1):4.CrossRef
195.
Tanioka M, Masaki T, Ono R, Nagano T, Otoshi-Honda E, Matsumura Y, et al. Molecular analysis of DNA polymerase eta gene in Japanese patients diagnosed as xeroderma pigmentosum variant type. J Investig Dermatol. 2007;127(7):1745–51.PubMedCrossRef
196.
Yang JQ, Chen XY, Engle MY, Wang JY. Multiple facial basal cell carcinomas in xeroderma pigmentosum treated with topical imiquimod 5% cream. Dermatol Ther. 2015;28(4):243–7.PubMedCrossRef
197.
Yarosh D, Klein J, O’Connor A, Hawk J, Rafal E, Wolf P. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet (London, England). 2001;357(9260):926–9.CrossRef
198.
Giustini S, Miraglia E, Berardesca E, Milani M, Calvieri S. Preventive long-term effects of a topical film-forming medical device with ultra-high UV protection filters and DNA repair enzyme in xeroderma pigmentosum: a retrospective study of eight cases. Case Rep Dermatol. 2014;6(3):222–6.PubMedPubMedCentralCrossRef
199.
Fassihi H, Sethi M, Fawcett H, Wing J, Chandler N, Mohammed S, et al. Deep phenotyping of 89 xeroderma pigmentosum patients reveals unexpected heterogeneity dependent on the precise molecular defect. Proc Natl Acad Sci USA. 2016;113(9):E1236–45.PubMedCrossRef
200.
Pena SD, Evans J, Hunter AG. COFS syndrome revisited. Birth Defects Orig Artic Ser. 1978;14(6b):205–13.PubMed
201.
Capell BC, Tlougan BE, Orlow SJ. From the rarest to the most common: insights from progeroid syndromes into skin cancer and aging. J Investig Dermatol. 2009;129(10):2340–50.PubMedCrossRef
202.
Yew YW, Giordano CN, Spivak G, Lim HW. Understanding photodermatoses associated with defective DNA repair: photosensitive syndromes without associated cancer predisposition. J Am Acad Dermatol. 2016;75(5):873–82.PubMedCrossRef
203.
Wilson BT, Stark Z, Sutton RE, Danda S, Ekbote AV, Elsayed SM, et al. The Cockayne Syndrome Natural History (CoSyNH) study: clinical findings in 102 individuals and recommendations for care. Genet Med Off J Am Coll Med Genet. 2016;18(5):483–93.
204.
205.
206.
207.
Kraemer KH, Patronas NJ, Schiffmann R, Brooks BP, Tamura D, DiGiovanna JJ. Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype–phenotype relationship. Neuroscience. 2007;145(4):1388–96.PubMedPubMedCentralCrossRef
208.
Hosseini M, Ezzedine K, Taieb A, Rezvani HR. Oxidative and energy metabolism as potential clues for clinical heterogeneity in nucleotide excision repair disorders. J Investig Dermatol. 2015;135(2):341–51.PubMedCrossRef
209.
210.
211.
Itoh T, Ono T, Yamaizumi M. A new UV-sensitive syndrome not belonging to any complementation groups of xeroderma pigmentosum or Cockayne syndrome: siblings showing biochemical characteristics of Cockayne syndrome without typical clinical manifestations. Mutat Res. 1994;314(3):233–48.PubMedCrossRef
212.
Horibata K, Iwamoto Y, Kuraoka I, Jaspers NG, Kurimasa A, Oshimura M, et al. Complete absence of Cockayne syndrome group B gene product gives rise to UV-sensitive syndrome but not Cockayne syndrome. Proc Natl Acad Sci USA. 2004;101(43):15410–5.PubMedCrossRef
213.
Nardo T, Oneda R, Spivak G, Vaz B, Mortier L, Thomas P, et al. A UV-sensitive syndrome patient with a specific CSA mutation reveals separable roles for CSA in response to UV and oxidative DNA damage. Proc Natl Acad Sci USA. 2009;106(15):6209–14.PubMedCrossRef
214.
Fujiwara Y, Ichihashi M, Kano Y, Goto K, Shimizu K. A new human photosensitive subject with a defect in the recovery of DNA synthesis after ultraviolet-light irradiation. J Investig Dermatol. 1981;77(3):256–63.PubMedCrossRef
215.
Guo J, Hanawalt PC, Spivak G. Comet-FISH with strand-specific probes reveals transcription-coupled repair of 8-oxoGuanine in human cells. Nucleic Acids Res. 2013;41(16):7700–12.PubMedPubMedCentralCrossRef
216.
Cleaver JE. Photosensitivity syndrome brings to light a new transcription-coupled DNA repair cofactor. Nat Genet. 2012;44(5):477–8.PubMedCrossRef
217.
Cleaver JE, Brennan-Minnella AM, Swanson RA, Fong KW, Chen J, Chou KM, et al. Mitochondrial reactive oxygen species are scavenged by Cockayne syndrome B protein in human fibroblasts without nuclear DNA damage. Proc Natl Acad Sci USA. 2014;111(37):13487–92.PubMedCrossRef
218.
Chatre L, Biard DS, Sarasin A, Ricchetti M. Reversal of mitochondrial defects with CSB-dependent serine protease inhibitors in patient cells of the progeroid Cockayne syndrome. Proc Natl Acad Sci USA. 2015;112(22):E2910–9.PubMedCrossRef
219.
Spivak G, Itoh T, Matsunaga T, Nikaido O, Hanawalt P, Yamaizumi M. Ultraviolet-sensitive syndrome cells are defective in transcription-coupled repair of cyclobutane pyrimidine dimers. DNA Repair. 2002;1(8):629–43.PubMedCrossRef
220.
221.
Gaillard H, Aguilera A. Transcription coupled repair at the interface between transcription elongation and mRNP biogenesis. Biochem Biophys Acta. 2013;1829(1):141–50.PubMed
222.
Brown AC, Belser RB, Crounse RG, Wehr RF. A congenital hair defect: trichoschisis with alternating birefringence and low sulfur content. J Investig Dermatol. 1970;54(6):496–509.PubMedCrossRef
223.
Faghri S, Tamura D, Kraemer KH, Digiovanna JJ. Trichothiodystrophy: a systematic review of 112 published cases characterises a wide spectrum of clinical manifestations. J Med Genet. 2008;45(10):609–21.PubMedPubMedCentralCrossRef
224.
Brooks BP, Thompson AH, Clayton JA, Chan CC, Tamura D, Zein WM, et al. Ocular manifestations of trichothiodystrophy. Ophthalmology. 2011;118(12):2335–42.PubMedPubMedCentralCrossRef
225.
Petrin JH, Meckler KA, Sybert VP. A new variant of trichothiodystrophy with recurrent infections, failure to thrive, and death. Pediatr Dermatol. 1998;15(1):31–4.PubMedCrossRef
226.
Shahrabani-Gargir L, Shomrat R, Yaron Y, Orr-Urtreger A, Groden J, Legum C. High frequency of a common Bloom syndrome Ashkenazi mutation among Jews of Polish origin. Genet Test. 1998;2(4):293–6.PubMedCrossRef
227.
German J, Takebe H. Bloom’s syndrome. XIV. The disorder in Japan. Clin Genet. 1989;35(2):93–110.PubMedCrossRef
228.
229.
Killen MW, Stults DM, Adachi N, Hanakahi L, Pierce AJ. Loss of Bloom syndrome protein destabilizes human gene cluster architecture. Hum Mol Genet. 2009;18(18):3417–28.PubMedCrossRef
230.
Nicotera TM, Notaro J, Notaro S, Schumer J, Sandberg AA. Elevated superoxide dismutase in Bloom’s syndrome: a genetic condition of oxidative stress. Can Res. 1989;49(19):5239–43.
231.
Lindor NM, Furuichi Y, Kitao S, Shimamoto A, Arndt C, Jalal S. Rothmund-Thomson syndrome due to RECQ4 helicase mutations: report and clinical and molecular comparisons with Bloom syndrome and Werner syndrome. Am J Med Genet. 2000;90(3):223–8.PubMedCrossRef
232.
Guerrero-Gonzalez GA, Martinez-Cabriales SA, Hernandez-Juarez AA, de Jesus Lugo-Trampe J, Espinoza-Gonzalez NA, Gomez-Flores M, et al. Rothmund–Thomson syndrome: a 13-year follow-up. Case Rep Dermatol. 2014;6(2):176–9.PubMedPubMedCentralCrossRef
233.
Wang LL, Levy ML, Lewis RA, Chintagumpala MM, Lev D, Rogers M, et al. Clinical manifestations in a cohort of 41 Rothmund–Thomson syndrome patients. Am J Med Genet. 2001;102(1):11–7.PubMedCrossRef
234.
Piquero-Casals J, Okubo AY, Nico MM. Rothmund–Thomson syndrome in three siblings and development of cutaneous squamous cell carcinoma. Pediatr Dermatol. 2002;19(4):312–6.PubMedCrossRef
235.
Stinco G, Governatori G, Mattighello P, Patrone P. Multiple cutaneous neoplasms in a patient with Rothmund–Thomson syndrome: case report and published work review. J Dermatol. 2008;35(3):154–61.PubMedCrossRef
236.
Wang LL, Plon SE. Rothmund–Thomson syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington; 1993–2018.
237.
Lai-Cheong JE, Parsons M, McGrath JA. The role of kindlins in cell biology and relevance to human disease. Int J Biochem Cell Biol. 2010;42(5):595–603.PubMedCrossRef
238.
Emmert H, Patel H, Brunton VG. Kindlin-1 protects cells from oxidative damage through activation of ERK signalling. Free Radical Biol Med. 2017;108:896–903.CrossRef
239.
Lai-Cheong JE, Liu L, Sethuraman G, Kumar R, Sharma VK, Reddy SR, et al. Five new homozygous mutations in the KIND1 gene in Kindler syndrome. J Investig Dermatol. 2007;127(9):2268–70.PubMedCrossRef
240.
Fine J, Mellerio JE. Kindler syndrome. In: Bolognia JLSJ, Cerroni L, Callen JP, Hruza GJ, Jorizzo JL, Lui H, Requena L, Schwarz T, Torrelo A, editors. Dermatology. 4th ed. New York: Elsevier Limited; 2018. p. 549.
241.
242.
243.
El Hachem M, Diociaiuti A, Proto V, Fortugno P, Zambruno G, Castiglia D, et al. Kindler syndrome with severe mucosal involvement in a large Palestinian pedigree. Eur J Dermatol. 2015;25(1):14–9.PubMed
244.
Lai-Cheong JE, Tanaka A, Hawche G, Emanuel P, Maari C, Taskesen M, et al. Kindler syndrome: a focal adhesion genodermatosis. Br J Dermatol. 2009;160(2):233–42.PubMedCrossRef
245.
Kern JS, Herz C, Haan E, Moore D, Nottelmann S, von Lilien T, et al. Chronic colitis due to an epithelial barrier defect: the role of kindlin-1 isoforms. J Pathol. 2007;213(4):462–70.PubMedCrossRef
246.
Almeida HL Jr, Heckler GT, Fong K, Lai-Cheong J, McGrath J. Sporadic Kindler syndrome with a novel mutation. An Bras Dermatol. 2013;88(6 Suppl 1):212–5.PubMedCrossRef
247.
Arita K, Wessagowit V, Inamadar AC, Palit A, Fassihi H, Lai-Cheong JE, et al. Unusual molecular findings in Kindler syndrome. Br J Dermatol. 2007;157(6):1252–6.PubMedCrossRef
248.
Ashton GH, McLean WH, South AP, Oyama N, Smith FJ, Al-Suwaid R, et al. Recurrent mutations in kindlin-1, a novel keratinocyte focal contact protein, in the autosomal recessive skin fragility and photosensitivity disorder, Kindler syndrome. J Investig Dermatol. 2004;122(1):78–83.PubMedCrossRef
249.
Emanuel PO, Rudikoff D, Phelps RG. Aggressive squamous cell carcinoma in Kindler syndrome. Skinmed. 2006;5(6):305–7.PubMedCrossRef
250.
Has C, Wessagowit V, Pascucci M, Baer C, Didona B, Wilhelm C, et al. Molecular basis of Kindler syndrome in Italy: novel and recurrent Alu/Alu recombination, splice site, nonsense, and frameshift mutations in the KIND1 gene. J Investig Dermatol. 2006;126(8):1776–83.PubMedCrossRef
251.
Lotem M, Raben M, Zeltser R, Landau M, Sela M, Wygoda M, et al. Kindler syndrome complicated by squamous cell carcinoma of the hard palate: successful treatment with high-dose radiation therapy and granulocyte-macrophage colony-stimulating factor. Br J Dermatol. 2001;144(6):1284–6.PubMedCrossRef
252.
Has C, Burger B, Volz A, Kohlhase J, Bruckner-Tuderman L, Itin P. Mild clinical phenotype of Kindler syndrome associated with late diagnosis and skin cancer. Dermatology. 2010;221(4):309–12.PubMedCrossRef
253.
Yazdanfar A, Hashemi B. Kindler syndrome: report of three cases in a family and a brief review. Int J Dermatol. 2009;48(2):145–9.PubMedCrossRef
254.
Lai-Cheong JE, Ussar S, Arita K, Hart IR, McGrath JA. Colocalization of kindlin-1, kindlin-2, and migfilin at keratinocyte focal adhesion and relevance to the pathophysiology of Kindler syndrome. J Investig Dermatol. 2008;128(9):2156–65.PubMedCrossRef
255.
Lai-Cheong JE, Moss C, Parsons M, Almaani N, McGrath JA. Revertant mosaicism in Kindler syndrome. J Investig Dermatol. 2012;132(3 Pt 1):730–2.PubMedCrossRef
256.
Maier K, He Y, Wolfle U, Esser PR, Brummer T, Schempp C, et al. UV-B-induced cutaneous inflammation and prospects for antioxidant treatment in Kindler syndrome. Hum Mol Genet. 2016;25(24):5339–52.PubMed
257.
Zapatero-Solana E, Garcia-Gimenez JL, Guerrero-Aspizua S, Garcia M, Toll A, Baselga E, et al. Oxidative stress and mitochondrial dysfunction in Kindler syndrome. Orphanet J Rare Dis. 2014;21(9):211.CrossRef
258.
Fazel N, Lim HW. Evaluation and management of the patient with photosensitivity. Dermatol Nurs. 2002;14(1):23–4 (7–30).PubMed
259.
Lim H, Hawk JLM. Evaluation of the photosensitive patients. In: Lim H, Hoenigsmann H, Hawk JLM, editors. Photodermatology. New York: Informa Healthcare; 2007. p. 139–67.
260.
261.
Tamura D, DiGiovanna JJ, Khan SG, Kraemer KH. Living with xeroderma pigmentosum: comprehensive photoprotection for highly photosensitive patients. Photodermatol Photoimmunol Photomed. 2014;30(2–3):146–52.PubMedCrossRef
262.
Kuwabara A, Tsugawa N, Tanaka K, Uejima Y, Ogawa J, Otao N, et al. High prevalence of vitamin D deficiency in patients with xeroderma pigmetosum-A under strict sun protection. Eur J Clin Nutr. 2015;69(6):693–6.PubMedCrossRef
Metadata
Title
Recent Developments in the Diagnosis and Management of Photosensitive Disorders
Authors
Amanda F. Nahhas
David M. Oberlin
Taylor L. Braunberger
Henry W. Lim
Publication date
01-10-2018
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 5/2018
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-018-0365-6

Other articles of this Issue 5/2018

American Journal of Clinical Dermatology 5/2018 Go to the issue

Review Article

Hair and Scalp Changes in Cutaneous and Systemic Lupus Erythematosus

Original Research Article

A Comprehensive Conceptual Model of the Experience of Chronic Itch in Adults

Short Communication

Serum Zinc Levels in Hidradenitis Suppurativa: A Case–Control Study

Leading Article

Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma

Short Communication

Piloting the Use of Smartphones, Reminders, and Accountability Partners to Promote Skin Self-Examinations in Patients with Total Body Photography: A Randomized Controlled Trial

Leading Article

Targeting the IL-23/IL-17 Pathway in Psoriasis: the Search for the Good, the Bad and the Ugly